Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


Articles published in Eur J Gastroenterol Hepatol

Retrieve available abstracts of 89 articles:
HTML format
Text format



Single Articles


    November 2018
  1. LYBECK C, Brenndorfer ED, Sallberg M, Montgomery SM, et al
    Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.
    Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316.
    PubMed     Text format     Abstract available


  2. DEMERDASH HM, Elyamany AS, Arida E
    Impact of direct-acting antivirals on leukocytic DNA telomere length in hepatitis C virus-related hepatic cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Nov 15. doi: 10.1097/MEG.0000000000001306.
    PubMed     Text format     Abstract available


    October 2018
  3. SHAHID M, Idrees M, Butt AM, Raza SM, et al
    Hepatitis C and G virus coinfection in Punjab, Pakistan: incidence and its correlation analysis with clinical data.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001302.
    PubMed     Text format     Abstract available


  4. LV DD, Wang ML, Chen EQ, Wu DB, et al
    A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Eur J Gastroenterol Hepatol. 2018 Oct 31. doi: 10.1097/MEG.0000000000001299.
    PubMed     Text format     Abstract available


  5. DRIEDGER M, Galanakis C, Doyle MA, Cooper CL, et al
    Direct-acting antiviral hepatitis C virus treatment perturbation of the metabolic milieu.
    Eur J Gastroenterol Hepatol. 2018 Oct 30. doi: 10.1097/MEG.0000000000001292.
    PubMed     Text format     Abstract available


  6. SHAH T, Hussain W, Ali N, Sardar S, et al
    Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study.
    Eur J Gastroenterol Hepatol. 2018 Oct 24. doi: 10.1097/MEG.0000000000001287.
    PubMed     Text format     Abstract available


  7. KRUGER K, Krauth C, Rossol S, Mauss S, et al
    Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-registry.
    Eur J Gastroenterol Hepatol. 2018 Oct 15. doi: 10.1097/MEG.0000000000001283.
    PubMed     Text format     Abstract available


  8. IBRAHIM EH, Marzouk SA, Zeid AE, Lashen SA, et al
    Role of the von Willebrand factor and the VITRO score as predictors for variceal bleeding in patients with hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Oct 2. doi: 10.1097/MEG.0000000000001272.
    PubMed     Text format     Abstract available


    September 2018
  9. ESSA M, Sabry A, Abdelsameea E, Tharwa ES, et al
    Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Sep 21. doi: 10.1097/MEG.0000000000001250.
    PubMed     Text format     Abstract available


  10. ATTIA D, Deterding K, Cornberg J, Gebel MJ, et al
    Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
    Eur J Gastroenterol Hepatol. 2018 Sep 19. doi: 10.1097/MEG.0000000000001259.
    PubMed     Text format     Abstract available


  11. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals: comparative analysis with non-direct-acting antivirals-treated patients.
    Eur J Gastroenterol Hepatol. 2018 Sep 7. doi: 10.1097/MEG.0000000000001264.
    PubMed     Text format     Abstract available


  12. FUKUI A, Kawabe N, Hashimoto S, Kamei H, et al
    Skeletal muscle mass depletion in patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001255.
    PubMed     Text format     Abstract available


    August 2018
  13. MUN EJ, Green P, Berry K, Ioannou GN, et al
    No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk.
    Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242.
    PubMed     Text format     Abstract available


  14. PASSERINI M, Schiavini M, Magni CF, Landonio S, et al
    Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 22. doi: 10.1097/MEG.0000000000001239.
    PubMed     Text format     Abstract available


  15. EL-NAHAAS SM, Fouad R, Elsharkawy A, Khairy M, et al
    High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001228.
    PubMed     Text format     Abstract available


  16. GAYAM V, Tiongson B, Khalid M, Mandal AK, et al
    Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Eur J Gastroenterol Hepatol. 2018 Aug 9. doi: 10.1097/MEG.0000000000001233.
    PubMed     Text format     Abstract available


    July 2018
  17. ELHELBAWY M, Abdel-Razek W, Alsebaey A, Hashim M, et al
    Insulin resistance does not impair response of chronic hepatitis C virus to direct-acting antivirals, and improves with the treatment.
    Eur J Gastroenterol Hepatol. 2018 Jul 18. doi: 10.1097/MEG.0000000000001215.
    PubMed     Text format     Abstract available


  18. ABDELAZIZ AO, Shousha HI, Said EM, A Soliman Z, et al
    Evaluation of liver steatosis, measured by controlled attenuation parameter, in patients with hepatitis C-induced advanced liver fibrosis and hepatocellular carcinoma.
    Eur J Gastroenterol Hepatol. 2018 Jul 17. doi: 10.1097/MEG.0000000000001196.
    PubMed     Text format     Abstract available


  19. SOLUND C, Andersen ES, Mossner B, Laursen AL, et al
    Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
    Eur J Gastroenterol Hepatol. 2018 Jul 9. doi: 10.1097/MEG.0000000000001192.
    PubMed     Text format     Abstract available


  20. HILL LA, Delmonte RJ, Andrews B, Richards L, et al
    Treatment of hepatitis C with direct-acting antivirals significantly reduces liver-related hospitalizations in patients with cirrhosis.
    Eur J Gastroenterol Hepatol. 2018 Jul 2. doi: 10.1097/MEG.0000000000001195.
    PubMed     Text format     Abstract available


  21. ALAVIAN SM, Sharafi H
    Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study'.
    Eur J Gastroenterol Hepatol. 2018;30:807-808.
    PubMed     Text format    


  22. OZCELIK F, Sertoglu E
    Povital role of platelet count in platelet-lymphocyte count used in distinguishing patients with significant liver fibrosis and insulin resistance.
    Eur J Gastroenterol Hepatol. 2018;30:807.
    PubMed     Text format    


    June 2018
  23. VIEJO LG, Herola AG, Lloret IS, Ruano FS, et al
    Screening of hepatitis C virus infection in adult general population in Spain.
    Eur J Gastroenterol Hepatol. 2018 Jun 22. doi: 10.1097/MEG.0000000000001190.
    PubMed     Text format     Abstract available


  24. SHANMUGAM RP, Balakrishnan S, Varadhan H, Shanmugam V, et al
    Prevalence of hepatitis B and hepatitis C infection from a population-based study in Southern India.
    Eur J Gastroenterol Hepatol. 2018 Jun 8. doi: 10.1097/MEG.0000000000001180.
    PubMed     Text format     Abstract available


    May 2018
  25. ISAKOV V, Paduta D, Viani RM, Enejosa JV, et al
    Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Eur J Gastroenterol Hepatol. 2018 May 14. doi: 10.1097/MEG.0000000000001166.
    PubMed     Text format     Abstract available


  26. TACHI Y, Hirai T, Kojima Y, Ishizu Y, et al
    Predictive ability of shear wave elastography for pruritus in chronic hepatitis C patients with sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 May 2. doi: 10.1097/MEG.0000000000001159.
    PubMed     Text format     Abstract available


  27. HUANG R, Wang J, Xia J, Hao Y, et al
    Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Eur J Gastroenterol Hepatol. 2018;30:583.
    PubMed     Text format    


  28. HASSANY M, Elsharkawy A, Maged A, Mehrez M, et al
    Hepatitis C virus treatment by direct-acting antivirals in successfully treated hepatocellular carcinoma and possible mutual impact.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001152.
    PubMed     Text format     Abstract available


  29. FOUAD R, Elbaz T, Abdel Alem S, Elsharkawy A, et al
    Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients.
    Eur J Gastroenterol Hepatol. 2018 May 1. doi: 10.1097/MEG.0000000000001151.
    PubMed     Text format     Abstract available


    April 2018
  30. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Controlled attenuation parameter for steatosis grading in chronic hepatitis C compared with digital morphometric analysis of liver biopsy: impact of individual elastography measurement quality.
    Eur J Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1097/MEG.0000000000001145.
    PubMed     Text format     Abstract available


  31. JIN CN, Chen JD, Sheng JF
    Vitamin D deficiency in hepatitis C virus infection: what is old? what is new?
    Eur J Gastroenterol Hepatol. 2018 Apr 16. doi: 10.1097/MEG.0000000000001134.
    PubMed     Text format     Abstract available


  32. SU YC, Lin PC, Yu HC, Wu CC, et al
    Hepatitis B virus reactivation in patients with resolved hepatitis B virus infection receiving chemotherapy or immunosuppressive therapy.
    Eur J Gastroenterol Hepatol. 2018 Apr 4. doi: 10.1097/MEG.0000000000001130.
    PubMed     Text format     Abstract available


    February 2018
  33. KOBAYASHI N, Iijima H, Tada T, Kumada T, et al
    Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Eur J Gastroenterol Hepatol. 2018 Feb 28. doi: 10.1097/MEG.0000000000001106.
    PubMed     Text format     Abstract available


  34. PYRSOPOULOS N, Trilianos P, Lingiah VA, Fung P, et al
    The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
    Eur J Gastroenterol Hepatol. 2018 Feb 23. doi: 10.1097/MEG.0000000000001101.
    PubMed     Text format     Abstract available


  35. SAGNELLI E, Stroffolini T, Sagnelli C, Cacopardo B, et al
    Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy.
    Eur J Gastroenterol Hepatol. 2018 Feb 20. doi: 10.1097/MEG.0000000000001099.
    PubMed     Text format     Abstract available


    January 2018
  36. ADHOUTE X, Penaranda G, Raoul JL, Sellier F, et al
    Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
    Eur J Gastroenterol Hepatol. 2018 Jan 30. doi: 10.1097/MEG.0000000000001082.
    PubMed     Text format     Abstract available


  37. LULLAU A, Petroff D, Batz O, Kramer J, et al
    Linkage to care of HbsAg-positive and anti-HCV-positive patients after a systematic screening approach in the German primary care setting.
    Eur J Gastroenterol Hepatol. 2018 Jan 10. doi: 10.1097/MEG.0000000000001052.
    PubMed     Text format     Abstract available


    December 2017
  38. ROULOT D, Thibault V, Laforest C, Fontaine H, et al
    Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
    Eur J Gastroenterol Hepatol. 2017 Dec 21. doi: 10.1097/MEG.0000000000001035.
    PubMed     Text format     Abstract available


  39. ALSEBAEY A, Elhelbawy M, Waked I
    Platelets-to-lymphocyte ratio is a good predictor of liver fibrosis and insulin resistance in hepatitis C virus-related liver disease.
    Eur J Gastroenterol Hepatol. 2017 Dec 13. doi: 10.1097/MEG.0000000000001013.
    PubMed     Text format     Abstract available


  40. BASHIR MH, Fazili J, Madhoun MF, Kanagala R, et al
    Impact of sustained virologic response on short-term clinical outcomes in hepatitis C-related cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Dec 1. doi: 10.1097/MEG.0000000000001032.
    PubMed     Text format     Abstract available


    November 2017
  41. MOSER S, Kozbial K, Laferl H, Schutz A, et al
    Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Eur J Gastroenterol Hepatol. 2017 Nov 8. doi: 10.1097/MEG.0000000000001027.
    PubMed     Text format     Abstract available


  42. SAAD Y, Awad A, Alakel W, Doss W, et al
    Data mining of routine laboratory tests can predict liver disease progression in Egyptian diabetic patients with hepatitis C virus (G4) infection: a cohort study of 71 806 patients.
    Eur J Gastroenterol Hepatol. 2017 Nov 2. doi: 10.1097/MEG.0000000000001008.
    PubMed     Text format     Abstract available


    October 2017
  43. ABDELAZIZ AO, Nabil MM, Abdelmaksoud AH, Shousha HI, et al
    De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2017 Oct 23. doi: 10.1097/MEG.0000000000001004.
    PubMed     Text format     Abstract available


  44. WIJARNPREECHA K, Chesdachai S, Jaruvongvanich V, Ungprasert P, et al
    Hepatitis C virus infection and risk of Parkinson's disease: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000000991.
    PubMed     Text format     Abstract available


  45. KORDA D, Lenard ZM, Gerlei Z, Jakab Z, et al
    Shear-wave elastography for the assessment of liver fibrosis in liver transplant recipients treated for hepatitis C virus recurrence.
    Eur J Gastroenterol Hepatol. 2017 Oct 18. doi: 10.1097/MEG.0000000000001003.
    PubMed     Text format     Abstract available


  46. FAN Y, Cao W, Di H, Liu C, et al
    Assessment of liver fibrosis with acoustic radiation force impulse in patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017;29:1190.
    PubMed     Text format    


    September 2017
  47. MOHAMED MS, Hanafy AS, Bassiony MAA, Hussein S, et al
    Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
    Eur J Gastroenterol Hepatol. 2017 Sep 25. doi: 10.1097/MEG.0000000000000963.
    PubMed     Text format     Abstract available


  48. TRIANTOS CK, Tsintoni A, Karaivazoglou K, Grigoropoulou X, et al
    Male hepatitis C patients' sexual functioning and its determinants.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000971.
    PubMed     Text format     Abstract available


  49. WRIGHT N, Reimer J, Somaini L, Roncero C, et al
    Are we ready to treat hepatitis C virus in individuals with opioid use disorder: assessment of readiness in European countries on the basis of an expert-generated model.
    Eur J Gastroenterol Hepatol. 2017 Sep 13. doi: 10.1097/MEG.0000000000000962.
    PubMed     Text format     Abstract available


  50. MILAZZO L, Magni C, Niero F, Schiavini M, et al
    Retreatment of chronic hepatitis C virus infection after unsuccessful therapy with all-oral direct-acting antiviral regimens: a real-life experience.
    Eur J Gastroenterol Hepatol. 2017 Sep 4. doi: 10.1097/MEG.0000000000000965.
    PubMed     Text format     Abstract available


  51. MOUSA N, Abdel-Razik A, Farag R, Shabana W, et al
    Do we need to screen for de-novo diabetes mellitus in chronic hepatitis C patients after a sustained virological response?
    Eur J Gastroenterol Hepatol. 2017;29:1004-1009.
    PubMed     Text format     Abstract available


    August 2017
  52. DOLMAZASHVILI E, Abutidze A, Chkhartishvili N, Karchava M, et al
    Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA e
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000964.
    PubMed     Text format     Abstract available


  53. SIMS OT, Guo Y, Shoreibah MG, Venkata K, et al
    Alcohol and substance use, race, and insurance status predict nontreatment for hepatitis C virus in the era of direct acting antivirals: a retrospective study in a large urban tertiary center.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000961.
    PubMed     Text format     Abstract available


  54. MANGLA N, Mamun R, Weisberg IS
    Viral hepatitis screening in transgender patients undergoing gender identity hormonal therapy.
    Eur J Gastroenterol Hepatol. 2017 Aug 29. doi: 10.1097/MEG.0000000000000950.
    PubMed     Text format     Abstract available


  55. KARAIVAZOGLOU K, Tsermpini EE, Assimakopoulos K, Triantos C, et al
    Sexual functioning in patients with chronic hepatitis C: a systematic review.
    Eur J Gastroenterol Hepatol. 2017 Aug 22. doi: 10.1097/MEG.0000000000000949.
    PubMed     Text format     Abstract available


  56. MIOTTO N, Mendes LC, Zanaga LP, Goncales ESL, et al
    Predictors of early discontinuation of interferon-free direct antiviral agents in patients with hepatitis C virus and advanced liver fibrosis: results of a real-life cohort.
    Eur J Gastroenterol Hepatol. 2017 Aug 10. doi: 10.1097/MEG.0000000000000944.
    PubMed     Text format     Abstract available


    July 2017
  57. POGORZELSKA J, Lapinska M, Kalinowska A, Lapinski TW, et al
    Helicobacter pylori infection among patients with liver cirrhosis.
    Eur J Gastroenterol Hepatol. 2017 Jul 11. doi: 10.1097/MEG.0000000000000928.
    PubMed     Text format     Abstract available


    June 2017
  58. VEIGA ZST, Villela-Nogueira CA, Fernandes FF, Cavalcanti MG, et al
    Transient elastography evaluation of hepatic and spleen stiffness in patients with hepatosplenic schistosomiasis.
    Eur J Gastroenterol Hepatol. 2017;29:730-735.
    PubMed     Text format     Abstract available


    May 2017
  59. STROFFOLINI T, Sagnelli E, Almasio PL, Andriulli A, et al
    Etiological factors of chronic hepatitis in Italy: a 2014 national survey.
    Eur J Gastroenterol Hepatol. 2017 May 19. doi: 10.1097/MEG.0000000000000907.
    PubMed     Text format     Abstract available


  60. WAHID B, Saleem K, Ali A, Rafique S, et al
    Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000895.
    PubMed     Text format    


  61. KOHLA MAS, Abbasy M, Abozeid M, El-Abd O, et al
    Assessment of liver fibrosis with acoustic radiation force impulse imaging versus liver histology in patients with chronic hepatitis C: a pilot study.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000903.
    PubMed     Text format     Abstract available


  62. CHEN D, Luo S, Ben Q, Lu L, et al
    Prevalence of hepatitis B and C and factors for infection and nonimmune in inflammatory bowel disease patients in China.
    Eur J Gastroenterol Hepatol. 2017;29:509-515.
    PubMed     Text format     Abstract available


  63. SOURIANARAYANANE A, Talluri J, Humar A, McCullough AJ, et al
    Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis.
    Eur J Gastroenterol Hepatol. 2017;29:516-523.
    PubMed     Text format     Abstract available


    April 2017
  64. CORDERO-RUIZ P, Carmona-Soria I, Rodriguez-Tellez M, Caunedo-Alvarez A, et al
    Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon and ribavirin antiviral therapy: clinical and fibrosis impact of treatment response.
    Eur J Gastroenterol Hepatol. 2017 Apr 25. doi: 10.1097/MEG.0000000000000886.
    PubMed     Text format     Abstract available


  65. MARCELLIN F, Protopopescu C, Esterle L, Wittkop L, et al
    Anger and quality of life in patients co-infected with HIV and hepatitis C virus: a cross-sectional study (ANRS CO13-HEPAVIH).
    Eur J Gastroenterol Hepatol. 2017 Apr 17. doi: 10.1097/MEG.0000000000000883.
    PubMed     Text format     Abstract available


  66. TABERNILLA A, Grandal M, Pernas B, Castro-Iglesias A, et al
    Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration.
    Eur J Gastroenterol Hepatol. 2017 Apr 13. doi: 10.1097/MEG.0000000000000882.
    PubMed     Text format     Abstract available


    March 2017
  67. SHERIGAR JM, Gayam V, Khan A, Mukhtar O, et al
    Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C.
    Eur J Gastroenterol Hepatol. 2017 Mar 24. doi: 10.1097/MEG.0000000000000871.
    PubMed     Text format     Abstract available


  68. JI F, Tian C, Li Z, Deng H, et al
    Ledipasvir and sofosbuvir combination for hepatitis C virus infection in three patients aged 85 years and older.
    Eur J Gastroenterol Hepatol. 2017 Mar 21. doi: 10.1097/MEG.0000000000000873.
    PubMed     Text format    


  69. TANWAR S, Trembling PM, Hogan BJ, Srivastava A, et al
    Noninvasive markers of liver fibrosis: on-treatment changes of serum markers predict the outcome of antifibrotic therapy.
    Eur J Gastroenterol Hepatol. 2017;29:289-296.
    PubMed     Text format     Abstract available


    February 2017
  70. ZHENG YX, Zhou PC, Zhou RR, Fan XG, et al
    The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2017 Feb 24. doi: 10.1097/MEG.0000000000000867.
    PubMed     Text format     Abstract available


  71. TAVARES RC, Feldner AC, Pinho JR, Uehara SN, et al
    Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection.
    Eur J Gastroenterol Hepatol. 2017 Feb 23. doi: 10.1097/MEG.0000000000000866.
    PubMed     Text format     Abstract available


  72. RONCERO C, Littlewood R, Vega P, Martinez-Raga J, et al
    Chronic hepatitis C and individuals with a history of injecting drugs in Spain: population assessment, challenges for successful treatment.
    Eur J Gastroenterol Hepatol. 2017 Feb 22. doi: 10.1097/MEG.0000000000000855.
    PubMed     Text format     Abstract available


  73. SU F, Beste LA, Green PK, Berry K, et al
    Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients.
    Eur J Gastroenterol Hepatol. 2017 Feb 13. doi: 10.1097/MEG.0000000000000858.
    PubMed     Text format     Abstract available


  74. NORTH CS, Pollio DE, Sims OT, Jain MK, et al
    An effectiveness study of group psychoeducation for hepatitis C patients in community clinics.
    Eur J Gastroenterol Hepatol. 2017 Feb 13. doi: 10.1097/MEG.0000000000000860.
    PubMed     Text format     Abstract available


  75. SILVA MJ, Pereira C, Loureiro R, Balsa C, et al
    Hepatitis C in a Mobile Low-Threshold Methadone Program.
    Eur J Gastroenterol Hepatol. 2017 Feb 1. doi: 10.1097/MEG.0000000000000843.
    PubMed     Text format     Abstract available


  76. LIONCO LC, de Mattos AA, Horbe AF, Costabeber AM, et al
    Treatment of hepatocellular carcinoma using transarterial chemoembolization: a real-life, single-centre study from Southern Brazil.
    Eur J Gastroenterol Hepatol. 2017;29:225-230.
    PubMed     Text format     Abstract available


    January 2017
  77. THONNES S, Friedel H, Frohlich H
    The number of patients with chronic hepatitis C in times of new therapy options: a retrospective observational study on German health insurance funds data.
    Eur J Gastroenterol Hepatol. 2017 Jan 12. doi: 10.1097/MEG.0000000000000819.
    PubMed     Text format     Abstract available


    December 2016
  78. TOSON EA, Shiha GE, El-Mezayen HA, Samir W, et al
    Noninvasive estimation of liver fibrosis in biopsy-proven hepatitis C virus-infected patients: angiogenic fibrogenic link.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  79. LAPI F, Capogrosso Sansone A, Mantarro S, Simonetti M, et al
    Hepatitis C virus infection: opportunities for an earlier detection in primary care.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  80. MCEWAN P, Selvapatt N, Brown A, Thursz M, et al
    A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  81. TURNER BJ, Liang Y, Singal A
    FIB-4 and imaging for measuring fibrosis in hepatitis C virus.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


  82. NORDSTROM EM, Keniston A, Baouchi F, Martinez-Camacho A, et al
    Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  83. WIJARNPREECHA K, Thongprayoon C, Ungprasert P
    Impact of caffeine in hepatitis C virus infection: a systematic review and meta-analysis.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  84. SCHULZ M, Beha D, Plehm K, Zollner C, et al
    High prevalence of anti-hepatitis E virus antibodies in outpatients with chronic liver disease in a university medical center in Germany.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  85. BERT F, Rindermann A, Abdelfattah MA, Stahmeyer JT, et al
    High prevalence of chronic hepatitis B and C virus infection in a population of a German metropolitan area: a prospective survey including 10 215 patients of an interdisciplinary emergency unit.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  86. ABDEL-RAZIK A, Elhelaly R, Elzehery R, El-Diasty A, et al
    Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Eur J Gastroenterol Hepatol. 2016;28:599-605.
    PubMed     Text format     Abstract available


    March 2016
  87. GULATI R, Nawaz M, Pyrsopoulos NT
    Comparative analysis of online patient education material pertaining to hepatitis and its complications.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  88. CARVALHANA SC, Leitao J, Alves AC, Bourbon M, et al
    Hepatitis B and C prevalence in Portugal: disparity between the general population and high-risk groups.
    Eur J Gastroenterol Hepatol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  89. OZDEN HT
    Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey.
    Eur J Gastroenterol Hepatol. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: